CAPS
MCID: CTS005
MIFTS: 43

Catastrophic Antiphospholipid Syndrome (CAPS)

Categories: Blood diseases, Bone diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Catastrophic Antiphospholipid Syndrome

MalaCards integrated aliases for Catastrophic Antiphospholipid Syndrome:

Name: Catastrophic Antiphospholipid Syndrome 19 58 71 75
Catastrophic Antiphospholipid Antibody Syndrome 19
Cryopyrin-Associated Periodic Syndromes 71
Thrombotic Storm 19
Catastrophic Aps 58
Caps 58

Characteristics:


Age Of Onset:

Adult 58

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases
Rare haematological diseases


Summaries for Catastrophic Antiphospholipid Syndrome

Orphanet: 58 A rare systemic autoimmune disease characterized by acute onset of life-threatening thromboses in three or more organs either simultaneously or within less than a week, in the presence of serum antiphospholipid antibodies (such as lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein 1 antibodies), and with histopathological confirmation of small-vessel occlusion in at least one affected organ. The condition occurs in a small subset of patients with antiphospholipid syndrome, often precipitated by infection, trauma, or surgery.

MalaCards based summary: Catastrophic Antiphospholipid Syndrome, also known as catastrophic antiphospholipid antibody syndrome, is related to antiphospholipid syndrome and cryopyrin-associated periodic syndrome. The drugs Plasminogen and Ambrisentan have been mentioned in the context of this disorder. Affiliated tissues include endothelial, bone and kidney, and related phenotypes are arthralgia and arterial thrombosis

GARD: 19 Catastrophic antiphospholipid syndrome (CAPS) is a rare form of antiphospholipid syndrome (APS). In CAPS multiple blood clots form throughout the body over a short period of time (usually within a week). CAPS is a medical emergency, as clots can cause life-threatening multi-organ failure. The cause of CAPS is unknown. A widely accepted explanation is that it is caused by a combination of genetic changes (making one more susceptible to CAPS) and an environmental trigger, such as an infection, trauma, or surgery.

Wikipedia: 75 Catastrophic antiphospholipid syndrome (CAPS), also known as Asherson's syndrome, is a rare autoimmune... more...

Related Diseases for Catastrophic Antiphospholipid Syndrome

Diseases related to Catastrophic Antiphospholipid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 267)
# Related Disease Score Top Affiliating Genes
1 antiphospholipid syndrome 11.6
2 cryopyrin-associated periodic syndrome 11.1
3 thrombotic microangiopathy 10.7
4 thrombocytopenia 10.7
5 thrombophilia due to thrombin defect 10.7
6 systemic lupus erythematosus 10.7
7 lupus erythematosus 10.6
8 systemic lupus erythematosus 1 10.6
9 hemolytic anemia 10.6
10 disseminated intravascular coagulation 10.6
11 adult respiratory distress syndrome 10.6
12 autoimmune disease 10.5
13 purpura 10.5
14 respiratory failure 10.5
15 hellp syndrome 10.5
16 thrombotic thrombocytopenic purpura, hereditary 10.5
17 thrombotic thrombocytopenic purpura 10.5
18 pulmonary embolism 10.5
19 acute kidney failure 10.4
20 vasculitis 10.4
21 hemolytic uremic syndrome, atypical 1 10.4
22 hemolytic-uremic syndrome 10.4
23 cardiogenic shock 10.4
24 primary agammaglobulinemia 10.4
25 stroke, ischemic 10.4
26 libman-sacks endocarditis 10.4
27 pre-eclampsia 10.4
28 vitamin k deficiency bleeding 10.4
29 heparin-induced thrombocytopenia 10.4
30 deficiency anemia 10.3
31 thrombosis 10.3
32 eclampsia 10.3
33 toxic shock syndrome 10.3
34 thrombophilia 10.3
35 connective tissue disease 10.3
36 diffuse alveolar hemorrhage 10.3
37 pregnancy loss, recurrent 1 10.3
38 endocarditis 10.3
39 thrombocytopenia due to platelet alloimmunization 10.3
40 splenic infarction 10.3
41 glomerulonephritis 10.3
42 systemic scleroderma 10.3
43 lymphoma, mucosa-associated lymphoid type 10.2
44 marginal zone b-cell lymphoma 10.2
45 scleroderma, familial progressive 10.2
46 thrombocytopenic purpura, autoimmune 10.2
47 down syndrome 10.2
48 premature ovarian failure 7 10.2
49 vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome 10.2
50 pulmonary hypertension 10.2

Graphical network of the top 20 diseases related to Catastrophic Antiphospholipid Syndrome:



Diseases related to Catastrophic Antiphospholipid Syndrome

Symptoms & Phenotypes for Catastrophic Antiphospholipid Syndrome

Human phenotypes related to Catastrophic Antiphospholipid Syndrome:

58 30 (show all 45)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002829
2 arterial thrombosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0004420
3 deep venous thrombosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0002625
4 coombs-positive hemolytic anemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0004844
5 microangiopathic hemolytic anemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001937
6 abnormality of serum cytokine level 58 30 Frequent (33%) Frequent (79-30%)
HP:0011112
7 peripheral thrombosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0002641
8 anticardiolipin igg antibody positivity 58 30 Frequent (33%) Frequent (79-30%)
HP:0020136
9 anti-beta 2 glycoprotein i antibody positivity 58 30 Frequent (33%) Frequent (79-30%)
HP:0032376
10 seizure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001250
11 arthritis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001369
12 abnormal heart valve morphology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001654
13 myocardial infarction 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001658
14 thrombocytopenia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001873
15 skin ulcer 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0200042
16 transient ischemic attack 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002326
17 migraine 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002076
18 pulmonary embolism 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002204
19 cutis marmorata 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000965
20 amaurosis fugax 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100576
21 preeclampsia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100602
22 systemic lupus erythematosus 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002725
23 arterial occlusion 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0025324
24 lupus anticoagulant 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0025343
25 superficial thrombophlebitis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002638
26 abnormal heart valve physiology 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0031653
27 chorea 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002072
28 avascular necrosis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0010885
29 angina pectoris 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001681
30 abnormality of the kidney 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000077
31 myocarditis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0012819
32 pulmonary arterial hypertension 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002092
33 gastrointestinal infarctions 58 30 Very rare (1%) Very rare (<4-1%)
HP:0005244
34 gangrene 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100758
35 dementia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000726
36 eclampsia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100601
37 acute encephalopathy 58 30 Very rare (1%) Very rare (<4-1%)
HP:0006846
38 abnormal jugular vein morphology 58 30 Very rare (1%) Very rare (<4-1%)
HP:3000042
39 retinal arterial occlusion 58 30 Very rare (1%) Very rare (<4-1%)
HP:0025326
40 venous thrombosis 58 Frequent (79-30%)
41 stroke 58 Occasional (29-5%)
42 abnormality of the nervous system 58 Occasional (29-5%)
43 spontaneous abortion 58 Frequent (79-30%)
44 antiphospholipid antibody positivity 58 Obligate (100%)
45 abnormal thrombosis 58 Very frequent (99-80%)

Drugs & Therapeutics for Catastrophic Antiphospholipid Syndrome

Drugs for Catastrophic Antiphospholipid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Plasminogen Approved Phase 4 9001-91-6
2
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
3
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
4 Fibrinolytic Agents Phase 4
5 Tissue Plasminogen Activator Phase 4
6 Hormones Phase 4
7 Liver Extracts Phase 4
8 Antihypertensive Agents Phase 4
9 Hormone Antagonists Phase 4
10 Diuretics, Potassium Sparing Phase 4
11 diuretics Phase 4
12 Natriuretic Peptide, Brain Phase 4
13 Mineralocorticoids Phase 4
14 Mineralocorticoid Receptor Antagonists Phase 4
15
Ginseng Investigational, Nutraceutical Phase 4 50647-08-0
16
Rilonacept Approved, Investigational Phase 3 501081-76-1
17
Calcium polycarbophil Approved Phase 2, Phase 3 126040-58-2
18 Cinnamon Approved Phase 2, Phase 3
19
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
20 Analgesics Phase 3
21 Anti-Inflammatory Agents Phase 3
22 Antibodies, Monoclonal Phase 3
23 Psyllium Phase 2, Phase 3
24 Juzentaihoto Phase 2, Phase 3
25 Mitogens Phase 2, Phase 3
26 Analgesics, Opioid Phase 3
27 Narcotics Phase 3
28 Immunoglobulins Phase 3
29 Antibodies Phase 3
30
Eculizumab Approved, Investigational Phase 2 219685-50-4
31
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
32
Flecainide Approved, Withdrawn Phase 2 54143-55-4 3356
33
Imipramine Approved Phase 2 50-49-7 3696
34
Moricizine Approved, Investigational, Withdrawn Phase 2 31883-05-3 34633
35
Encainide Approved, Investigational, Withdrawn Phase 2 66778-36-7 48041
36
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643
37
Histamine Approved, Investigational Phase 2 51-45-6 774
38
Tranilast Investigational Phase 2 53902-12-8 5282230
39 Complement System Proteins Phase 2
40 Antibodies, Antiphospholipid Phase 2
41 Immunosuppressive Agents Phase 2
42 Immunologic Factors Phase 2
43 Adrenergic Agents Phase 2
44 Anti-Arrhythmia Agents Phase 2
45 Sodium Channel Blockers Phase 2
46 Psychotropic Drugs Phase 2
47 Antidepressive Agents, Tricyclic Phase 2
48 Antidepressive Agents Phase 2
49 Calcineurin Inhibitors Phase 2
50 Neurotransmitter Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands Completed NCT02645916 Phase 4 Danggui-Sayuk-Ga-Osuyu-Saenggang-tang;Placebo: corn starch
2 Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet : a Randomized, Double-blind, Placebo-controlled Trial Completed NCT01664156 Phase 4 Korean red ginseng;Placebo
3 Cathflo Activase (Alteplase) Pediatric Study (CAPS) Completed NCT00307580 Phase 4 Cathflo Activase (Alteplase)
4 The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study) Terminated NCT02253394 Phase 4 Ambrisentan plus Spironolactone;Ambrisentan plus Placebo
5 An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Completed NCT00685373 Phase 3 Canakinumab (ACZ885)
6 An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan Completed NCT00991146 Phase 3 canakinumab
7 An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS) Completed NCT01576367 Phase 3
8 A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS) Completed NCT01302860 Phase 3 ACZ885
9 An Open Label Study to Assess the Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada Completed NCT01105507 Phase 3 canakinumab (company code: ACZ885D)
10 IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs Completed NCT00288704 Phase 3 rilonacept 160 mg;Placebo
11 A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome Completed NCT00465985 Phase 3 ACZ885;Placebo
12 Efficacy and Safety of Ojeok-san on Korean Patients With Cold Hypersensitivity in the Hands and Feet - A Randomized, Double-blinded, Placebo Controlled, Multi-center Pilot Study Completed NCT03083522 Phase 3 Ojeok-San;Placebo
13 Efficacy and Safety of Ucha-Shinki-Hwan on Korean Patients With Cold Hypersensitivity in the Hands and Feet-Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial Completed NCT03790033 Phase 2, Phase 3 Ucha-Shinki-Hwan;Placebo
14 Efficacy and Safety of Sipjeondaebo-tang on Korean Patients With Cold Hypersensitivity in the Hands and Feet (SDT) Completed NCT03374345 Phase 2, Phase 3 Sipjeondaebo-tang Granule;Placebo
15 Multi-center Pivotal Clinical Trial to Compare the Safety and Effectiveness of Procedural Sedation in GI Endoscopy: A Computer-Assisted Personalized Sedation (CAPS) Device Versus Current Standard of Care Completed NCT00452426 Phase 3
16 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
17 Heat Loss Prevention in Delivery Room: a Prospective, Randomised, Controlled Trial of Polyethylene Caps in Very Preterm Infants Completed NCT00930917 Phase 3
18 A Multi-Center, Open Label, 24-Month Treatment Study to Establish the Safety, Tolerability, Efficacy, Pharmacokinetics of Canakinumab (Anti-IL-1 Beta Antibody) in Patients With NOMID / CINCA Syndrome Terminated NCT00770601 Phase 3 Canakinumab
19 Eculizumab to Enable Renal Transplantation in Patients With History of Antiphospholipid Antibody Syndrome or Catastrophic Antiphospholipid Antibody Syndrome Completed NCT01029587 Phase 2 Eculizumab
20 A Phase 2a, Prospective, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS) Completed NCT05186051 Phase 2 ZYIL1 capsule
21 A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS) Completed NCT01045772 Phase 2 rilonacept
22 Pilot Trial of Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling (ELASTO-GEL CAPS)in Breast Cancer Patients Completed NCT00515762 Phase 2
23 PreCoCa - "Prehospital Cooling With Cool-Caps" Completed NCT00398671 Phase 2
24 Cardiac Arrhythmia Pilot Study (CAPS) Completed NCT00000504 Phase 2 encainide;moricizine;flecainide;imipramine
25 Ph 2 Double-blind, Double-dummy, Multicenter, Prospective, Rand Study of PK of LCP-Tacro™ Tablets Once Daily, Compared to Prograf® Caps, Twice Daily, for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients Completed NCT01666951 Phase 2 LCP-Tacro tablets;Prograf
26 Efficacy and Safety of Tranilast in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS): A Single-Arm Prospective Cohort Study Recruiting NCT03923140 Phase 2 Tranilast
27 An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) Recruiting NCT04868968 Phase 2 DFV890
28 An Open Label, Single Arm Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of HL2351 in Patients With Cryopyrin Associated Periodic Syndromes Terminated NCT02853084 Phase 2 HL2351
29 A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease Terminated NCT00069329 Phase 1, Phase 2 anakinra
30 A Phase 2a, Open-Label, Single-Arm Study to Investigate the Safety and Efficacy of ATI-450 for the Maintenance of Remission in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) Previously Managed With Anti-IL-1 Therapy Terminated NCT04524858 Phase 2 ATI-450
31 A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome (FCAS) / Muckle-Wells Syndrome (MWS) and Behcet's Disease (BD) Withdrawn NCT01211977 Phase 1, Phase 2 XOMA 052
32 A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of IZD334 in Healthy Adult Participants as Well as an Open-label Cohort to Confirm the Safety, Pharmacokinetics, and Pharmacodynamics in Adult Patients With Cryopyrin-Associated Periodic Syndromes Completed NCT04086602 Phase 1 IZD334;Placebos
33 A Phase 1, Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Inzomelid in Healthy Adult Participants as Well as an Open Label Cohort to Confirm the Safety, Pharmacokinetics, and Pharmacodynamics of Inzomelid in Adult Patients With Cryopyrin-Associated Periodic Syndromes Completed NCT04015076 Phase 1 Inzomelid;Placebo
34 The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria Completed NCT00214851 Phase 1 Kineret (anakinra)
35 Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland) Completed NCT02507648 Phase 1 Oseltamivir;Tamiflu®
36 Double-blind Randomised Placebo-controlled Study of Prolardii Gastro-resistant (GR) Caps in the Prevention and Treatment of Antibiotic-associated Diarrhoea. Unknown status NCT03256708
37 Cohort Study to Assess Electronic-caps Defined Adherence Patterns - Virological Outcome Relationship Amongst HIV-1 Infected Subjects Receiving Dolutegravir-Based Antiretroviral Therapy) Unknown status NCT02878642
38 Non-interventional PASS to Evaluate Safety of Kineret in Treatment of CAPS in Routine Clinical Care With Regard to Serious Infections, Malignancies, Injection Site Reactions, Allergic Reactions, Medication Errors Including Re-use of Syringe Completed NCT02326376 anakinra (Kineret)
39 An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients Completed NCT01213641
40 International CAPS Registry: Operated Cases and Cases With Advanced Disease Among High-risk Individuals Participating in a Pancreatic Cancer Surveillance Program; a Case-control Study Completed NCT02703545
41 Care After Pregnancy Study (CAPS): Randomized Controlled Trial of Patient Engagement After Pregnancy Completed NCT04257552
42 Coaching Alternative Parenting Strategies (CAPS) Study: Targeting Neurobiological and Behavioral Mechanisms of Self-regulation in High-risk Families Completed NCT02684903
43 Understanding the Feasibility of Ripple Health Smart Pill Caps in Clinical Settings, and the Devices' Effects on Medical Interventions. Completed NCT05192928
44 Radioprotective Light-weight Caps in the Interventional Cardiology Setting: a Randomized Controlled Trial Completed NCT01620658
45 Study on the Reduction of Catheter-related Infections by Use of Self-disinfecting Venous and Arterial Access Caps Completed NCT04534348
46 Clinical and Multi-omics Cross-phenotyping of Patients With Autoimmune and Auto-inflammatory Diseases Recruiting NCT02466217
47 Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases) Recruiting NCT02974595
48 Pathogenesis and Genetic Basis of Physical Induced Urticarial Syndromes Recruiting NCT00887939
49 Clinical Characteristic and Quality of Life Assessment in Adulthood of Patients With Cryopyrin Associated Periodic Syndrome Recruiting NCT04856540
50 The Impact of Structured Caregiver Peer Support (CaPS) on ART Adherence and Viral Suppression Among Children Living With HIV in Nigeria Recruiting NCT04222270

Search NIH Clinical Center for Catastrophic Antiphospholipid Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


anakinra

Genetic Tests for Catastrophic Antiphospholipid Syndrome

Anatomical Context for Catastrophic Antiphospholipid Syndrome

Organs/tissues related to Catastrophic Antiphospholipid Syndrome:

MalaCards : Endothelial, Bone, Kidney, Heart, Brain, Skin, Breast

Publications for Catastrophic Antiphospholipid Syndrome

Articles related to Catastrophic Antiphospholipid Syndrome:

(show top 50) (show all 10887)
# Title Authors PMID Year
1
Building the Toolbox of Devices to Optimize a Practice in Submucosal Endoscopy. 62
36375879 2023
2
Injectable bone cements: What benefits the combination of calcium phosphates and bioactive glasses could bring? 62
35510175 2023
3
Retinoic acid control of pax8 during renal specification of Xenopus pronephros involves hox and meis3. 62
36279927 2023
4
Decoupling the role of chemistry and microstructure in hMSCs response to an osteoinductive calcium phosphate ceramic. 62
35475029 2023
5
The effect of ethanol on fibrillar hydrogels formed by glycyrrhizic acid monoammonium salt. 62
36356444 2023
6
Health impact assessments of shipping and port-sourced air pollution on a global scale: A scoping literature review. 62
36191619 2023
7
[Adhesion of urologists to the recommendations of the French Urological Association Cancer Committee (CCAFU) in the imaging work-up of localized prostate cancer]. 62
36344379 2022
8
Dataset on modelling a synthetic oil rim reservoirs for optimizing oil production during gas cap blow down strategy. 62
36426095 2022
9
Inbreeding effects on telomeres in hatchling sand lizards (Lacerta agilis): An optimal family affair? 62
36208022 2022
10
Microplastics in Malaysian bottled water brands: Occurrence and potential human exposure. 62
36279991 2022
11
Development of Novel Markers for Yield in Hevea brasiliensis Muell. Arg. Based on Candidate Genes from Biosynthetic Pathways Associated with Latex Production. 62
35296963 2022
12
Evaluation of real-life data on the use of inhaler devices, including satisfaction and adherence to treatment, by community pharmacists in partnership with pulmonary disease specialists. 62
36332164 2022
13
Two Cases of Severe Amanita Muscaria Poisoning Including a Fatality. 62
36210279 2022
14
Carotid plaque components and other carotid artery features associated with risk of stroke: A systematic review and meta-analysis. 62
36334373 2022
15
Neurodegenerative diseases-Caps: a capsule network based early screening system for the classification of neurodegenerative diseases. 62
36397832 2022
16
In-vitro NLRP3 functional test assists the diagnosis of cryopyrin-associated periodic syndrome (CAPS) patients: A Brazilian cooperation. 62
36244670 2022
17
Subacute parkinsonism due to systemic lupus erythematosus and catastrophic antiphospholipid syndrome. 62
36463907 2022
18
Differentiating and Managing Rare Thrombotic Microangiopathies During Pregnancy and Postpartum. 62
36455925 2022
19
Vagal control moderates the association between endothelial function and PTSD symptoms in women with T2DM. 62
36247837 2022
20
The feasibility of eye movement desensitization and reprocessing (EMDR) for older adults with posttraumatic stress disorder (PTSD) and comorbid psychiatric and somatic disorders. 62
36455886 2022
21
Efficacy and mechanisms of mobile application-delivered Acceptance and Commitment Therapy for posttraumatic stress disorder in China: Study protocol for a randomized controlled trial. 62
36426200 2022
22
Treatment efficacy of tDCS and predictors of treatment response in patients with post-traumatic stress disorder. 62
36055537 2022
23
Augmenting trauma-focused psychotherapy for post-traumatic stress disorder with brief aerobic exercise in Australia: a randomised clinical trial. 62
36436532 2022
24
Findings from a pilot study of Trauma Center Trauma-Sensitive Yoga versus cognitive processing therapy for PTSD related to military sexual trauma among women Veterans. 62
35820575 2022
25
Hyperbaric Oxygen Therapy for Veterans With Treatment-resistant PTSD: A Longitudinal Follow-up Study. 62
36433746 2022
26
A Review of Precision Insulin Management With Smart Insulin Pens: Opening Up the Digital Door to People on Insulin Injection Therapy. 62
36326233 2022
27
Design, Modeling and Fabrication of a Novel Class V Flextensional Transducer: The Sea-Shell. 62
36417721 2022
28
Presentation of cryopyrin-associated periodic fever syndrome as chronic, afebrile urticaria in a 12-month-old female. 62
36382474 2022
29
Interaction between Antiphospholipid Antibodies and Protein C Anticoagulant Pathway: A Narrative Review. 62
35021251 2022
30
Equally potent: Nlrp3 mutation in macrophages or neutrophils is sufficient to drive autoinflammation. 62
36194522 2022
31
[Heart involvement in systemic lupus erythematosus and antiphospholipid syndrome]. 62
36088204 2022
32
Selective Induction of Intrinsic Apoptosis in Retinoblastoma Cells by Novel Cationic Antimicrobial Dodecapeptides. 62
36432697 2022
33
Rare mutations in NLRP3 and NLRP12 associated with familial cold autoinflammatory syndrome: two Chinese pedigrees. 62
35852776 2022
34
AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review. 62
35262642 2022
35
A Study on the Factors Affecting Anger in Patients With Post-traumatic Stress Disorder. 62
36444156 2022
36
METTL1 drives tumor progression of bladder cancer via degrading ATF3 mRNA in an m7G-modified miR-760-dependent manner. 62
36396627 2022
37
High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets. 62
35238757 2022
38
Diagnostic and Translational Utility of the Secondary Traumatic Stress Clinical Algorithm (STS-CA). 62
34507502 2022
39
Peripheral biomarkers of oxidative stress in dogs with acute pancreatitis. 62
36086902 2022
40
The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children. 62
36069338 2022
41
A computational study on strontium ion modified hydroxyapatite-fibronectin interactions. 62
36373734 2022
42
Mega Meta-QTLs: A Strategy for the Production of Golden Barley (Hordeum vulgare L.) Tolerant to Abiotic Stresses. 62
36360327 2022
43
Evaluating the effect of the protector cap for castable implant abutments on reverse tightening values. 62
36402626 2022
44
Predicting Collagen Triple Helix Stability through Additive Effects of Terminal Residues and Caps. 62
36409045 2022
45
Bacterial contamination and organic residue after reprocessing in duodenoscopes with disposable distal caps compared with duodenoscopes with fixed distal caps: a randomized trial. 62
35718069 2022
46
Thrombotic storm in coronavirus disease 2019: from underlying mechanisms to its management. 62
36346830 2022
47
Telomeres in clinical diabetes research - Moving towards precision medicine in diabetes care? 62
36427630 2022
48
Catastrophic antiphospholipid syndrome presenting initially as severe abdominal pain. 62
36394309 2022
49
Predictive factors of sun protection behaviour among global airline pilots. 62
35324018 2022
50
Caps Captioning: A Modern Image Captioning Approach Based on Improved Capsule Network. 62
36366079 2022

Variations for Catastrophic Antiphospholipid Syndrome

Expression for Catastrophic Antiphospholipid Syndrome

Search GEO for disease gene expression data for Catastrophic Antiphospholipid Syndrome.

Pathways for Catastrophic Antiphospholipid Syndrome

GO Terms for Catastrophic Antiphospholipid Syndrome

Sources for Catastrophic Antiphospholipid Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....